|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abingworth Management, of London, announced the initial $53 million closing of the Abingworth Bioequities Fund, its seventh life sciences fund and the first solely for investments in quoted stocks. The firm said funds will be invested in under-appreciated quoted stocks that have the potential to produce high returns over a two- to four-year holding period. A second offering of shares is planned for late this year.
Active Biotech AB, of Stockholm, Sweden, completed its Phase I study in 30 healthy volunteers of its candidate 57-57 for the treatment of systemic lupus erythematosus, and the drug was well tolerated in all of the studied dose levels, both as a single ...